Clinical Trial

Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 26, 2025 (before its estimated December 2, 2025 completion). Its status may not reflect the trial's current state.
Summary
Virometix AG, is conducting research into a vaccine (V-212) to prevent pneumococcal disease, which is any type of illness caused by infection with a bacterium called Streptococcus pneumoniae (S. pneumoniae). This trial is being conducted to obtain insight into the body's immune response and possible adverse effects of the trial vaccine in healthy adult volunteers. Three different doses will be evaluated to identify an optimal dose for future trials. The trial is a prospective (collects data into the future), randomised, double-blind, phase I, first in human, placebo-controlled trial which will be conducted at one centre in Belgium. A total of 60 trial participants will be enrolled.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-07.
Status change: Recruiting → Active, Not Recruiting 2025-08-25
Trial Details
NCT Number NCT06975319
Lead Sponsor Virometix
Collaborators: CR2O
Conditions Healthy, Immunisation Against Streptococcus Pneumoniae
Enrollment 60 participants
Start Date 2025-01-29
Primary Completion 2025-12-02 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-26